UK government advised against mass prostate cancer screening by expert committee | BBC News

Key Concepts

• Prostate Cancer Screening: The process of testing men for prostate cancer, typically through PSA blood tests and potentially further investigations like MRI scans and biopsies.
• National Screening Committee (NSC): The UK body responsible for evaluating evidence and making decisions on national screening programs.
• PSA (Prostate-Specific Antigen) Test: A blood test that measures the level of PSA, a protein produced by the prostate gland. Elevated PSA levels can indicate prostate cancer, but also other non-cancerous conditions.
• Overdiagnosis and Overtreatment: The identification and treatment of slow-growing or indolent prostate cancers that would not have caused harm or death to the individual during their lifetime.
• Harm vs. Benefit Analysis: The core principle of screening program evaluation, where the potential benefits (lives saved, reduced mortality) are weighed against the potential harms (false positives, anxiety, side effects of invasive procedures and treatments).
• Genetic Mutations: Specific changes in DNA that can increase the risk of developing certain cancers, including aggressive forms of prostate cancer.
• High-Risk Groups: Specific demographics or individuals with a higher likelihood of developing prostate cancer, including Black men and those with a family history of the disease.
• Transform Trial: A large-scale research trial initiated by Prostate Cancer UK to gather more evidence on prostate cancer screening, particularly for underrepresented groups.
• Real-World Evidence: Data collected from routine clinical practice and patient experiences, used to supplement evidence from controlled trials.

NHS Decision Against Routine Prostate Cancer Screening

The National Screening Committee (NSC) in the UK has officially decided against implementing routine prostate cancer screening for all men over 50. This decision comes despite prostate cancer being the most common cancer in men globally, with 1.4 million new cases in 2022. The NSC's primary concern is that the potential harm associated with mass testing may outweigh the number of lives saved.

Reasoning Behind the Decision

The committee has ruled out mass testing for all men over 50, and also against specific screening programs for Black men, who have a greater risk of the disease, and for men with a family history of prostate cancer. The only group who will be offered screening are men with specific genetic mutations known to cause aggressive tumors.

The core argument against a national testing regime is that it could "do more harm than good." This is attributed to the complex nature of prostate cancer:

• Variable Aggressiveness: For some individuals, prostate cancer can be very aggressive. However, for others, it can be slow-growing and asymptomatic, meaning they might live with it for many years without noticing, potentially dying from other causes.
• Harm from Treatment: The concern is that men diagnosed with slow-growing cancers might undergo aggressive treatments, including biopsies and therapies, leading to side effects such as incontinence and sexual dysfunction. These side effects could potentially have a greater negative impact on their quality of life than the cancer itself.

Statistics and Impact

• UK Statistics: In the UK alone, approximately 55,000 men are diagnosed with prostate cancer annually, and around 12,000 die from the disease.
• Comparison to Other Cancers: Unlike lung cancer or breast cancer, there is currently no national screening system for prostate cancer.
• Campaigners: Despite the NSC's decision, there has been significant campaigning for increased testing from charities, families affected by the disease, and high-profile figures such as former Prime Minister David Cameron, Rishi Sunak, and Olympic cyclist Sir Chris Hoy.

Sir Chris Hoy's Statement

Sir Chris Hoy, who was diagnosed with prostate cancer two years ago, released a statement expressing his disappointment: "I am extremely disappointed and saddened by the recommendation announced by the National Screening Committee today to rule out against a national screening for men at high risk of prostate cancer. I know firsthand that by sharing my story following my own diagnosis two years ago, many, many lives have been saved. Early screening and diagnosis saves lives."

Personal Experiences and Perspectives

The broadcast features interviews with individuals directly affected by prostate cancer, offering personal insights into the importance of early detection.

Paul Ly's Story

Paul Ly was diagnosed with prostate cancer by chance in October 2021. He visited his doctor for an unrelated issue and a PSA test was included as part of a routine blood panel. His PSA reading was 56, significantly higher than the considered dangerous threshold of over four. Paul had no symptoms and no prior knowledge of prostate cancer, describing the diagnosis as a "bombshell" and feeling like it was "the end of my life." He underwent radiotherapy and hormone therapy for three years, and his locally advanced cancer was successfully treated. He emphasizes that if it had been left longer, the outcome could have been very different.

Family History and Screening

Paul also shared the impact of his diagnosis on his family. Following his diagnosis, his four sons were advised to get tested if they were over 40. His eldest son, aged 43 at the time, was also diagnosed with prostate cancer. He was told that without early detection, he could have died within five years, at the age of 48. This personal experience highlights the critical role of family history in assessing risk and the potential benefits of screening for those with a genetic predisposition.

Prostate Cancer UK's Response and Future Directions

Laura Kirby, CEO of Prostate Cancer UK, expressed deep disappointment with the NSC's decision, stating that the evidence still indicates that the benefits of screening are outweighed by the harms.

Addressing Evidence Gaps for Black Men

• Higher Risk: Black men are twice as likely to develop prostate cancer, with one in four Black men expected to be diagnosed in their lifetime.
• Insufficient Data: The NSC's decision against screening for Black men was partly due to insufficient evidence that they would not be put at more harm than benefit.
• Transform Trial: Prostate Cancer UK has launched the "Transform" trial to address these evidence gaps. This trial will focus on collecting data from Black men, with 10% of participants being recruited from this demographic.
• Real-World Evidence: The charity is also investing £1 million in collecting real-world evidence to build a stronger case for future screening recommendations for Black men.

Overdiagnosis and Overtreatment Concerns

Laura Kirby acknowledged the NSC's expertise and the process they followed. She noted that Prostate Cancer UK had hoped that advancements in diagnostic tools, such as MRI scans, might have shifted the balance in favor of screening. However, the evidence presented clearly indicates that the benefits of finding aggressive cancers that can be treated and cured do not outweigh the harms of overtreatment for slow-growing cancers that would not have caused serious risk.

Call for Change in Guidelines

Prostate Cancer UK urges the government to:

1. Change Guidelines: Amend the guidelines to allow doctors to have proactive conversations with men in high-risk groups, rather than turning them away if they don't present with symptoms.
2. Drive Awareness: Continue to raise awareness so that men in high-risk groups (men over 50, Black men over 45, and men with a family history) proactively discuss PSA blood tests with their GPs.

Conclusion and Future Outlook

The decision by the NHS National Screening Committee against routine prostate cancer screening is a significant one, driven by a careful assessment of potential harms versus benefits. While this is a blow to many, particularly those who have campaigned for increased testing, the focus now shifts to addressing the evidence gaps, especially for high-risk groups like Black men, through initiatives like the Transform trial. The ultimate goal remains to find a balance where more lives can be saved with reduced harm, which will require further research and potentially a revision of screening guidelines in the future.